FORM PTO 1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 11-2000)							
TRANSMITTAL LETTER TO THE UNITED STATES	LBNL-201-US						
DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPLICATION No. (grafil wifesen 7 C/R 16)						
CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATES	PRIORITY DATE CLAIMED						
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATES PCT/US03/12380 April 21, 2003	April 22, 2002						
DNA DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT PHOSPHORYLATION							
SITES AND ANTIBODIES THERETO							
APPLICANT(S) FOR DO/EO/US Chen, et al.							
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the f	i						
1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.							
This is a SECOND or SUBSEQUENT submission of items concerning a filing 35 U.S.C. 371							
This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.							
4. X The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).							
5. x A copy of the International Application as filed (35 U.S.C. 371 (c)(2))							
a. is attached hereto (required only if not communicated by the International Bureau).							
b. has been communicated by the International Bureau.							
c. X is not required, as the application was filed in the United States Receiving Office (RO/US).							
X An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).							
a. X is attached hereto.							
b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7. X Amendments to the claims of the International Application under PCT Ar							
a. are attached hereto (required only if not communicated by the Interna							
b. have been communicated by the International Bureau.	b. have been communicated by the International Bureau.						
c. have not been made; however, the time limit for making such amendr	have not been made; however, the time limit for making such amendments has NOT expired.						
d. X have not been made and will not be made.	X have not been made and will not be made.						
8. An English language translation of the amendments to the claims under P	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).						
9. X An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).						
10. An English language translation of the annexes to the International Prelin Article 36 (35 U.S.C. 371 (c)(5)).	ninary Examination Report under PCT						
Items 11 to 20 below concern document(s) or information included:	·						
11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12. X An assignment document for recording. A separate cover sheet in compliant	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13. X A FIRST preliminary amendment.	A FIRST preliminary amendment.						
14. A SECOND or SUBSEQUENT preliminary amendment.	A SECOND or SUBSEQUENT preliminary amendment.						
15. A substitute specification.	A substitute specification.						
16. A change of power of attorney and/or address letter.	A change of power of attorney and/or address letter.						
17. A computer-readable form of the sequence listing in accordance with PC	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.						
18. A second copy of the published international application under 35 U.S.C.	A second copy of the published international application under 35 U.S.C. 154(d)(4).						
20. Other items or information							

U.S. APPLICATION TO GIAMON TO 37CFR 1.55 6 1 INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER  DCT// ISO3/12380 I BNI -201-IIS						
7 0170000712500			LBNL-201-US			
17. X The following fees are submitted:				CALCULATIONS	PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)):  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO And International Search Report not prepared by the EPO or JPO						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report will be prepared by the EPO or JPO \$						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$  International preliminary examination fee (37 CFR 1.482) paid to USPTO						
but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$395.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO						
And all claims satisfied provisions of PCT Article 33(1)-(4)						
ENTER APPROPRIATE BASIC FEE AMOUNT =			\$ 395.00			
Surcharge of \$ for furnishing the oath or declaration later than			s			
20 x 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).			<u></u>			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		<b>_</b>	
Total claims	20 =	9	18	\$		
Independent claims MULTIPLE DEPENDE	1-3 =	oable)	X	\$ \$	+	
MOCITI CE DEI ENDE		L OF ABOVE CALC		\$	<del></del>	
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above			\$			
Are reduced by ½.						
SUBTOTAL =			\$ 395.00	<del></del>		
Processing fee of \$ For furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +			\$			
TOTAL NATIONAL FEE =			\$			
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment Must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31)  ( Per property).			\$ 40.00			
TOTAL FEES ENCLOSED =			\$ 435.00			
			Amount to be Refunded:	\$		
				Charged:	\$	
A check in the amount of \$						
b. X Please charge my Deposit Account No. 50-0624 in the amount of \$ \$435.00  To cover the above fees. A duplicate copy of this sheet is enclosed.						
c. X The Commissioner is hereby authorized to charge any additional fees which may be required or credit  Any overpayment to my Deposit Account No. 50-0624 A duplicate copy of this sheet is enclosed.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.						
SEND ALL CORRESPONDENCE TO: Customer No. 24972  James R. Crawford  SIGNATURE:						
FULBRIGHT & JAWORSKI L.L.P.  James R. Crawford					·	
666 Fifth Avenue NAME/ New York, New York 10103 (212) 318-3148 39,155					<del></del>	
				<del> </del>		

1 5 OCT 2004

20/511561
DT04 Rec'd PCT/PT0
1 5 001
Early favorable consideration of the patent application is respectfully solicited.

Respectfully submitted,

666 Fifth Avenue New York, New York 10103 (212) 318-3000

(212) 318-3400 (Fax)

James R. Crawford Reg. No. 39,155

Fulbright & Jaworski, L.L.P.

Attorneys for Applicant

## VIA Express Mail

I hereby certify that this correspondence is being deposited with the U.S. Postal Service by Express Mail: EV 331561485 US an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22313-1450 on the date shown below:

Date: 10/15/04
Eileen Sheffield Eileen Stoffwi

DT04 Rec a PCT/PTO 1 5 OCT 2004

LBNL-201-US)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Chen, et al.

Serial No

Filed:

For

DNA DEPENDENT PROTEIN KINASE CATALYTIC

SUBUNIT PHOSPHORYLATION SITES AND ANTIBODIES

**THERETO** 

Art Unit

To be assigned

Examiner

To be assigned

October 15, 2004

MS: PCT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA. 22313-1450

## STATEMENT PURSUANT TO 37 CFR 1.823(B)

Dear Sir:

Submitted herewith for filing in connection with the above-referenced patent application is a computer readable copy of the Sequence Listing included in the application.

I hereby state that I have reviewed the paper copy of the Sequence Listing, as required by 37 C.F.R. § 1.821(c), and have reviewed the computer readable form of the Sequence Listing, as required by 37 C.F.R. § 1.821(e), and that the content of the paper and computer readable copies for the above-referenced patent application are the same as required by 37 C.F.R. § 1.821(f).

DT04 Rec'd PCT/PT0 1 5 OCT 2004

Certificate of Express Mail

This mail is being sent by Express Mail No. EV 331561485 US
In an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450
On OCTOBER 15, 2004

By Eileen Sheffield Shoffield

SUSBP1957EEA3